Barclays Analysts Give Bayer (BAYN) a €100.00 Price Target
Bayer (FRA:BAYN) received a €100.00 ($119.05) price target from research analysts at Barclays in a note issued to investors on Wednesday. The firm currently has a “sell” rating on the healthcare company’s stock. Barclays’ price target suggests a potential downside of 4.63% from the stock’s current price.
Several other brokerages have also commented on BAYN. Goldman Sachs Group set a €125.00 ($148.81) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Tuesday, November 7th. UBS set a €125.00 ($148.81) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Monday, November 6th. Berenberg Bank set a €124.00 ($147.62) price objective on shares of Bayer and gave the company a “neutral” rating in a research report on Friday, November 3rd. Jefferies Group set a €137.00 ($163.10) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Tuesday, November 14th. Finally, DZ Bank reissued a “buy” rating on shares of Bayer in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. Bayer currently has an average rating of “Buy” and a consensus price target of €122.19 ($145.46).
Shares of Bayer (BAYN) traded down €1.30 ($1.55) on Wednesday, reaching €104.85 ($124.82). The company had a trading volume of 2,713,786 shares. Bayer has a 52-week low of €86.60 ($103.10) and a 52-week high of €123.82 ($147.40).
ILLEGAL ACTIVITY NOTICE: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/06/barclays-analysts-give-bayer-bayn-a-100-00-price-target.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.